George L. Sing
Known title: DirectorCIK: 0001225471
Associated companies
Transaction History
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| REGN | ▲ Buy | Option Exercise | 9,212 | $4.8M | 12/30/2025 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 6,188 | $4.8M | 12/30/2025 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 1,948 | $1.4M | 12/31/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 3,338 | $1.4M | 12/31/2024 | View on chart |
| REGN | ▼ Sell | Gift | 1,200 | $0 | 9/4/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,000 | $827K | 5/3/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 877 | $827K | 5/3/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 500 | $207K | 2/26/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $495K | 2/26/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 500 | $207K | 2/26/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $498K | 2/26/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 500 | $207K | 2/23/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $493K | 2/23/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,000 | $413K | 2/22/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,000 | $413K | 2/22/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $960K | 2/22/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,000 | $413K | 2/22/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $965K | 2/22/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $970K | 2/22/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 500 | $207K | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $478K | 2/9/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 500 | $207K | 2/8/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $473K | 2/8/2024 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $617K | 2/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $614K | 2/28/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 2,000 | $1.2M | 2/25/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $655K | 11/22/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $660K | 11/22/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $655K | 11/19/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 4,000 | $2.6M | 11/18/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2,000 | $1.3M | 11/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2,000 | $1.3M | 11/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 2,000 | $1.3M | 11/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 750 | $488K | 11/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $335K | 8/30/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 250 | $168K | 8/30/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 300 | $202K | 8/30/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 500 | $338K | 8/30/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 150 | $101K | 8/26/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 705 | $444K | 8/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,000 | $628K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.